Drug intelligence / Profile preview

clofarabine + busulfan + antithymocyte globulin

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Intravenous

Overview

A reduced-toxicity conditioning regimen used prior to allogeneic hematopoietic stem cell transplantation for patients with high-risk hematologic malignancies. This combination provides effective disease control while maintaining a favorable safety profile compared to conventional myeloablative regimens. It consists of clofarabine (a purine nucleoside analog with strong anti-leukemic activity), busulfan (an alkylating agent), and antithymocyte globulin (an immunosuppressive agent that helps prevent graft rejection and GVHD).

Other names: Clofarabine-busulfan-ATG

Targets

RNR (Ribonucleotide reductase)DNA

Beyond the preview

Go deeper on clofarabine + busulfan + antithymocyte globulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clofarabine + busulfan + antithymocyte globulin.

Explore the full profile